NSE · SUNPHARMA · Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹4,924 Cr with net profit ₹609 Cr — a 12.36% net margin, versus 18.61% the period before.
Shareholding
As of 2026-06-30
- Promoter54.48%
- Public8.81%
- FII14.53%
- DII22.18%
7,10,246 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.29× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd.(this company) | ₹4,74,277 Cr | 174.93 | 5.68 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,16,701 Cr | 210.28 | 3.39 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,09,646 Cr | 86.89 | 4.05 | 18.59% | 18.86% |
| Lupin Limited | ₹1,09,544 Cr | 68.79 | 4.88 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,08,118 Cr | 194.78 | 6.63 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹95,025 Cr | 340.21 | 17.92 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹94,785 Cr | 428.53 | 2.5 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹89,978 Cr | 97.68 | 2.37 | 9.25% | 10.5% |
| Biocon Ltd. | ₹70,007 Cr | 546.71 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,572 Cr | 285.86 | 4.89 | 16.66% | 15.65% |
AI analysis
AI-generated · google/gemini-2.5-flashSun Pharmaceutical Industries Ltd. has a market capitalization of Rs 469,406 Cr. The company reported revenue of Rs 61,673.94 Cr with a revenue growth of 8.4%. Its profit margin stands at 19.72%, and it has an EPS of 51.8. The debt-to-equity ratio is 0.04.
Positives
- +The company has a low debt-to-equity ratio of 0.04.
- +The profit margin is 19.72%, indicating efficient operations.
- +Revenue grew by 8.4%.
Negatives
- −No quarterly results for annual periods after Mar 2026 were fully disclosed, with limited information for June, September, and December periods of 2025 indicated in annual.
- −Promoter pledge percentage, while currently at 1.65% in Jun 2026, has fluctuated in the past, reaching 4.34% in Jun 2017.
- −EBITDA decreased from Rs 4,795 Cr in Dec 2025 to Rs 3,637.23 Cr in Mar 2026.
Financial performance
Sun Pharmaceutical Industries Ltd. recorded revenue of Rs 61,673.94 Cr with an annual revenue growth of 8.4%. The company's net profit margin was 19.72%. For the quarter ending Mar 2026, revenue was Rs 14,611.79 Cr, generating a net profit of Rs 2,714.03 Cr. Quarterly EBITDA for the same period was Rs 3,637.23 Cr.
Profitability & Returns
The company's profitability is indicated by a return on equity (ROE) of 13.74% and a return on capital employed (ROCE) of 17.33%. The earnings per share (EPS) for the latest reported period is 51.8. The profit margin stands at 19.72%.
Balance Sheet
Sun Pharmaceutical Industries Ltd. maintains a low debt-to-equity ratio of 0.04, suggesting a limited reliance on debt financing. The book value per share is reported at 348.31.
Ownership & Pledges
Institutional holding stands at 36.71%, comprising 22.18% by DIIs and 14.53% by FIIs. Public shareholding is 8.81%. The promoter pledge percentage is 1.65% as of Jun 2026, with individual pledges including 85,000 shares held by Kumud Shantilal Shanghvi and 21,439,530 shares held by Raksha Sudhir Valia.
Promoter Shareholding History
Promoter pledged shares have shown fluctuation over time. The pledge percentage was 2.58% in Jun 2018, decreased to 2.35% in Mar 2018, and reached 4.34% in Jun 2017. As of Jun 2026, the promoter pledge is 1.65%. The number of shareholders has increased from 501,453 in Sep 2016 to 710,246 in Jun 2026.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Sun Pharmaceutical Industries Ltd.share price & fundamentals